Terflavoxate

Terflavoxate

SCHEMBL29385282

Cc1c(-c2ccccc2)oc2c(C(=O)OC(C)(C)CN3CCCCC3)cccc2c1=O

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.71
HTR1A P08908 3/20 0.71
ADRA1A P35348 3/20 0.71
KDM4E B2RXH2 2/20 0.71
CYP1A2 P05177 1/20 0.71
CHRM2 P08172 1/20 0.71
CYP3A4 P08684 1/20 0.71
ADRA2A P08913 1/20 0.71
ADORA3 P0DMS8 1/20 0.71
CYP2D6 P10635 1/20 0.71
CHRM1 P11229 1/20 0.71
ACHE P22303 1/20 0.71
SLC6A2 P23975 1/20 0.71
PDE4A P27815 1/20 0.71
OPRM1 P35372 1/20 0.71
DRD3 P35462 1/20 0.71
KCNH2 Q12809 1/20 0.71
HRH3 Q9Y5N1 1/20 0.71
ALDH1A1 P00352 6/20 0.52
SMN1; SMN2 Q16637 4/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Terflavoxate SCHEMBL668305 1.00 LMNA (0.71) LMNAHTR1AADRA1AKDM4ECYP1A2
Terflavoxate SCHEMBL5944360 0.99 LMNA (0.70) LMNAHTR1AADRA1AKDM4ECYP1A2
SCHEMBL8876605 0.86 LMNA (0.71) LMNAHTR1AADRA1AKDM4ECYP1A2
SCHEMBL10959014 0.86 LMNA (0.58) LMNAHTR1AADRA1AKDM4ECYP1A2
Hydrochloric Acid SCHEMBL8874296 0.86 LMNA (0.70) LMNAHTR1AADRA1AKDM4ECYP1A2
Flavoxate SCHEMBL29421720 0.83 LMNA (1.00) LMNAHTR1AADRA1AKDM4ECYP1A2
Flavoxate SCHEMBL25801 0.83 LMNA (1.00) LMNAHTR1AADRA1AKDM4ECYP1A2
Flavoxate SCHEMBL124540 0.82 LMNA (0.98) LMNAHTR1AADRA1AKDM4ECYP1A2
Flavoxate SCHEMBL29395220 0.82 LMNA (0.98) LMNAHTR1AADRA1AKDM4ECYP1A2
Flavoxate SCHEMBL1650335 0.81 LMNA (0.96) LMNAHTR1AADRA1AKDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4706683-A2 CHEWABLE FORMULATIONS Elanco Tiergesundheit AG (CH) 2026-03-11 EP disclosed
US-20230277448-A1 CHEWABLE FORMULATIONS ELANCO TIERGESUNDHEIT AG (CH) 2023-09-07 US disclosed
EP-4208155-A1 CHEWABLE FORMULATIONS Elanco Tiergesundheit AG (CH) 2023-07-12 EP disclosed
WO-2022049149-A1 CHEWABLE FORMULATIONS ELANCO TIERGESUNDHEIT AG (CH) 2022-03-10 WO disclosed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230277448-A1 CHEWABLE FORMULATIONS SI, TAS2R39, TAS2R31 LMNA 894/4885HTR1A 1933/4885ADRA1A 4146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.